Literature DB >> 4599859

Comparative clinical study of tobramycin and gentamicin.

J Klastersky, C Hensgens, A Henri, D Daneau.   

Abstract

Gentamicin and tobramycin have been compared in vitro and as single-drug therapy in patients with a serious infection caused by gram-negative rods. In vitro, a slight advantage of tobramycin over gentamicin has been found against Pseudomonas aeruginosa. Cross-resistance between gentamicin and tobramycin has been observed for gentamicin-resistant strains of P. aeruginosa and Providence but was not always present. The clinical effectiveness of gentamicin and tobramycin was similar: 14 (45.1%) out of the 31 patients in each series responded favorably. The clinical results were much better in urinary tract infections (66% of favorable responses) than in wound infections, pulmonary infections, septicemia, and meningitis (26% of favorable responses). The frequency of adverse reactions encountered in the present series was similar for both drugs.

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4599859      PMCID: PMC428934          DOI: 10.1128/AAC.5.2.133

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  7 in total

1.  Clinical significance of in vitro synergism between antibiotics in gram-negative infections.

Authors:  J Klastersky; R Cappel; D Daneau
Journal:  Antimicrob Agents Chemother       Date:  1972-12       Impact factor: 5.191

2.  Comparative study of tobramycin and gentamicin with special reference to anti-pseudomonas activity.

Authors:  J Klastersky; D Daneau; V de Maertelaer
Journal:  Clin Pharmacol Ther       Date:  1973 Jan-Feb       Impact factor: 6.875

3.  Is there complete cross-resistance of gram-negative bacilli to gentamicin and tobramycin?

Authors:  C C Crowe; E Sanders
Journal:  Antimicrob Agents Chemother       Date:  1972-11       Impact factor: 5.191

4.  Endotracheal gentamicin in bronchial infections in patients with tracheostomy.

Authors:  J Klastersky; C Geuning; E Mouawad; D Daneau
Journal:  Chest       Date:  1972-02       Impact factor: 9.410

5.  Disc plate method of microbiological antibiotic assay. II. Novel procedure offering improved accuracy.

Authors:  W W Davis; T R Stout
Journal:  Appl Microbiol       Date:  1971-10

6.  Tobramycin (nebramycin factor 6): in vitro activity against Pseudomonas aeruginosa.

Authors:  R D Meyer; L S Young; D Armstrong
Journal:  Appl Microbiol       Date:  1971-12

7.  Evaluation of the in vitro activity of tobramycin as compared with that of gentamicin sulfate.

Authors:  W H Traub; E A Raymond
Journal:  Appl Microbiol       Date:  1972-01
  7 in total
  11 in total

1.  Clinical and bacteriological evaluation of netilmicin in gram-negative infections.

Authors:  J Klastersky; F Meunier-Carpentier; L Coppens-Kahan; D Daneau; J M Prevost
Journal:  Antimicrob Agents Chemother       Date:  1977-10       Impact factor: 5.191

2.  Gentamicin and tobramycin penetration into synovial fluid.

Authors:  T H Dee; F Kozin
Journal:  Antimicrob Agents Chemother       Date:  1977-10       Impact factor: 5.191

3.  Aminoglycoside antibiotics and renal function: changes in urinary gamma-glutamyltransferase excretion.

Authors:  P R Beck; R B Thomson; A K Chaudhuri
Journal:  J Clin Pathol       Date:  1977-05       Impact factor: 3.411

4.  The use of tombramycin in the management of severe infections. Clinical and pharmacological data.

Authors:  D Baron; H Drugeon; F Nicolas; A Courtieu
Journal:  Eur J Intensive Care Med       Date:  1976-09

5.  Comparative activity of tobramycin and gentamicin against Pseudomonas, Proteus and Providencia species.

Authors:  I B Ducan; J L Penner
Journal:  Can Med Assoc J       Date:  1975-07-12       Impact factor: 8.262

6.  Therapy of Pseudomonas aeruginosa infections with tobramycin.

Authors:  D C Blair; F R Fekety; B Bruce; J Silva; G Archer
Journal:  Antimicrob Agents Chemother       Date:  1975-07       Impact factor: 5.191

Review 7.  Tobramycin: a review of its antibacterial and pharmacokinetic properties and therapeutic use.

Authors:  R N Brogden; R M Pinder; P R Sawyer; T M Speight; G S Avery
Journal:  Drugs       Date:  1976       Impact factor: 9.546

8.  [Concentration in bone and haematoma of the aminoglycoside antibiotic tobramycin (author's transl)].

Authors:  W Winkelmann; K P Schulitz; H Knothe; B Schoening
Journal:  Infection       Date:  1978       Impact factor: 3.553

9.  Antibiotic blood concentrations in patients successfully treated with tobramycin.

Authors:  M Fiala; S N Chatterjee
Journal:  Postgrad Med J       Date:  1981-09       Impact factor: 2.401

10.  Newer aminoglycosides--amikacin and tobramycin: an in-vitro comparison with kanamycin and gentamicin.

Authors:  A V Reynolds; J M Hamilton-Miller; W Brumfitt
Journal:  Br Med J       Date:  1974-09-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.